Breast Surgery — MCQs

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 51: Which flap is NOT typically used for breast reconstruction?

A. Transverse rectus abdominis myocutaneous flap
B. Latissimus dorsi myocutaneous flap
C. Pectoralis major myocutaneous flap (Correct Answer)
D. Transversus rectus abdominis free flap

Explanation: **Explanation:** Breast reconstruction aims to restore volume and contour following mastectomy. The choice of flap depends on the availability of donor tissue, the vascular pedicle, and whether the flap is pedicled or free. **Why Option C is the Correct Answer:** The **Pectoralis major myocutaneous flap** is primarily used in **Head and Neck reconstruction** (e.g., following oral cavity cancer resection). In breast surgery, the pectoralis major muscle is typically **preserved** (modified radical mastectomy) or used as a muscular pocket to cover a prosthetic implant. It is not used as a transposition flap for breast volume because it lacks sufficient bulk and its transposition would result in significant functional loss of the chest wall without providing the necessary aesthetic contour. **Analysis of Incorrect Options:** * **A & D (TRAM Flaps):** The **Transverse Rectus Abdominis Myocutaneous (TRAM)** flap is the "gold standard" for autologous breast reconstruction. It can be **pedicled** (based on superior epigastric vessels) or a **free flap** (based on deep inferior epigastric vessels). It provides excellent volume and a natural feel by using lower abdominal skin and fat. * **B (Latissimus Dorsi Flap):** This is a common **pedicled flap** based on the thoracodorsal artery. While it provides reliable skin coverage, it often lacks sufficient volume on its own and is frequently combined with a breast implant. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard:** TRAM flap (specifically the DIEP flap, which spares the muscle). * **Most common free flap:** DIEP (Deep Inferior Epigastric Perforator) flap. * **Blood supply of TRAM:** Superior epigastric (Pedicled); Deep inferior epigastric (Free). * **Blood supply of LD Flap:** Thoracodorsal artery (branch of the subscapular artery).

Question 52: What is the indication for sentinel lymph node biopsy in breast cancer?

A. Metastasis
B. Breast mass with palpable axillary node
C. Breast mass without palpable axillary node (Correct Answer)
D. Stage III cases

Explanation: **Explanation:** The **Sentinel Lymph Node Biopsy (SLNB)** is the gold standard for axillary staging in patients with early-stage breast cancer who have a **clinically negative axilla (cN0)**. The "sentinel node" is the first lymph node(s) to receive lymphatic drainage from the primary tumor; if this node is free of cancer, the remaining nodes in the axilla are highly likely to be clear, thus sparing the patient the morbidity of an Axillary Lymph Node Dissection (ALND). * **Why Option C is correct:** SLNB is indicated when there is **no clinical or radiological evidence of axillary metastasis** (non-palpable nodes). It aims to identify occult micrometastasis while avoiding complications like lymphedema, nerve injury, and shoulder stiffness associated with radical dissection. * **Why other options are incorrect:** * **Option A & B:** If metastasis is already proven or if there are **palpable, suspicious axillary nodes**, the patient is classified as clinically node-positive (cN+). These patients typically require a fine-needle aspiration (FNA) or core biopsy followed by ALND or neoadjuvant chemotherapy. * **Option D:** **Stage III** represents locally advanced breast cancer (large tumors or fixed nodes). These cases carry a high risk of lymphatic blockage or altered drainage patterns, making SLNB unreliable; ALND is generally the standard of care here. **High-Yield NEET-PG Pearls:** * **Tracers used:** Technetium-99m labeled sulfur colloid (radioactive) and/or Isosulfan/Methylene blue dye. * **Most accurate method:** The "Dual Technique" (using both dye and isotope) has the lowest false-negative rate (<5%). * **Contraindications:** Inflammatory breast cancer, biopsy-proven positive axillary nodes, and active infection in the axilla. * **Standard of care:** If the sentinel node is negative, no further axillary surgery is required.

Question 53: What is the most common variant of carcinoma of the breast?

A. Invasive lobular carcinoma
B. Invasive ductal carcinoma (Correct Answer)
C. Tubular carcinoma
D. Medullary carcinoma

Explanation: **Explanation:** **Invasive Ductal Carcinoma (IDC)**, specifically the "No Special Type" (NST), is the most common histological variant of breast cancer, accounting for approximately **75–80%** of all invasive breast malignancies. It originates in the milk ducts but breaks through the wall to invade the surrounding breast stroma. On clinical examination, it typically presents as a hard, painless, immobile mass due to significant desmoplastic reaction (fibrosis). **Analysis of Incorrect Options:** * **Invasive Lobular Carcinoma (ILC):** This is the second most common variant (approx. 10–15%). It is characterized by the loss of E-cadherin, leading to a "single-file" pattern of cells. It is notable for being more frequently bilateral and multicentric compared to IDC. * **Tubular Carcinoma:** A well-differentiated subtype of IDC with an excellent prognosis. However, it is rare, accounting for only about 1–2% of cases. * **Medullary Carcinoma:** A rare subtype (approx. 1–5%) often associated with BRCA1 mutations. Despite having high-grade features (fleshy consistency, lymphoid infiltrate), it generally carries a better prognosis than standard IDC. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Upper Outer Quadrant (due to the maximum volume of breast tissue). * **Most common benign tumor:** Fibroadenoma (Breast Mouse). * **Staging:** The TNM system is the most important prognostic factor; however, the **number of axillary lymph nodes involved** is the single most significant prognostic indicator for recurrence. * **Molecular Subtypes:** Luminal A is the most common molecular subtype and carries the best prognosis.

Question 54: Which of the following statements regarding breast self-examination is/are true?

A. It should be performed in different positions such as standing, sitting, and supine. (Correct Answer)
B. It is a method to improve T-cell survival rates.
C. In premenopausal women, it should be done approximately 2-3 days before the menstrual cycle.
D. It should only be started after the age of 35 years.

Explanation: **Explanation:** Breast Self-Examination (BSE) is a screening tool used to increase breast awareness and detect early changes. **1. Why Option A is Correct:** BSE must be performed in multiple positions (**standing, sitting, and supine**) to ensure all breast tissue is adequately palpated against the chest wall. Standing or sitting allows for the inspection of symmetry and skin changes (like dimpling), while the supine position flattens the breast tissue, making it easier to detect deep-seated lumps against the rib cage. **2. Why the other options are Incorrect:** * **Option B:** BSE is a screening method for early detection of breast cancer; it has no physiological link to **T-cell survival rates** or immunological enhancement. * **Option C:** In premenopausal women, BSE should be performed **7–10 days after the onset of menstruation** (the follicular phase). Just before the cycle, hormonal changes cause breast engorgement and tenderness, which can lead to false-positive findings or "lumpy" sensations. * **Option D:** While guidelines vary, it is generally recommended to start breast awareness/BSE from the **age of 20**. Starting at 35 is too late for establishing a baseline of "normal" breast texture. **Clinical Pearls for NEET-PG:** * **Triple Assessment:** The gold standard for breast lump evaluation includes Clinical Examination, Imaging (Mammography/Ultrasound), and Pathology (FNAC/Biopsy). * **Best Time for BSE:** Post-menopausal women should choose a fixed date every month (e.g., the 1st of the month). * **Technique:** Use the **pads of the middle three fingers** and follow a systematic pattern (e.g., vertical strip or circular method). * **Evidence:** Large trials (like the Shanghai trial) showed that BSE does not reduce mortality but significantly increases the number of benign biopsies; hence, modern guidelines emphasize **"Breast Awareness"** over rigid BSE protocols.

Question 55: Which of the following conditions is NOT typically associated with a large breast?

A. Filariasis
B. Giant fibroadenoma
C. Cystosarcoma phylloides
D. Schirrhous carcinoma (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Schirrhous carcinoma**. The underlying medical concept here is the distinction between **mass-forming/proliferative lesions** and **infiltrative/fibrotic lesions**. 1. **Why Schirrhous Carcinoma is the correct answer:** Schirrhous carcinoma (a subtype of Invasive Ductal Carcinoma) is characterized by an intense **desmoplastic reaction** (excessive formation of dense connective tissue). This fibrosis causes the tumor to contract, leading to **shrinkage of the breast tissue**, nipple retraction, and skin tethering. Therefore, it is associated with a **small, shrunken, and hard breast** rather than a large one. 2. **Why the other options are incorrect:** * **Filariasis (A):** Lymphatic obstruction by *Wuchereria bancrofti* leads to chronic lymphedema and massive enlargement of the breast (Elephantiasis of the breast). * **Giant Fibroadenoma (B):** Defined as a fibroadenoma >5 cm or >500g, these typically occur in adolescents and cause significant, rapid breast enlargement. * **Cystosarcoma Phylloides (C):** These are fibroepithelial tumors known for their rapid growth and potential to reach massive sizes, often replacing the entire breast volume. **NEET-PG High-Yield Clinical Pearls:** * **Schirrhous Carcinoma:** The most common clinical presentation is a "stony hard" fixed lump. On sectioning, it gives a characteristic "gritty" sensation (like cutting an unripe pear). * **Phylloides Tumor:** Characterized by a "leaf-like" growth pattern on histology. It is the most common cause of a massive breast lump in women aged 40–50. * **Differential for Massive Breast:** Giant fibroadenoma, Phylloides tumor, Breast abscess, and Gestational macromastia.

Question 56: All of the following are predisposing factors for breast carcinoma except?

A. Family history of breast carcinoma
B. First child at a younger age (Correct Answer)
C. Early menarche and late menopause
D. Nulliparous women

Explanation: The risk of breast carcinoma is heavily influenced by the cumulative lifetime exposure of breast tissue to endogenous estrogen. Factors that increase the number of menstrual cycles or prolong the period of estrogen exposure increase the risk. **Explanation of the Correct Answer:** * **Option B (First child at a younger age):** This is actually a **protective factor**, not a predisposing one. Early full-term pregnancy (ideally before age 20) leads to the terminal differentiation of mammary epithelial cells, making them less susceptible to carcinogenic transformation. It also results in a long period of amenorrhea (pregnancy and lactation), reducing the total number of lifetime ovulatory cycles. **Explanation of Incorrect Options:** * **Option A (Family history):** This is a major risk factor. Approximately 5-10% of cases are hereditary, often involving mutations in **BRCA1 or BRCA2** genes. A first-degree relative with breast cancer doubles the risk. * **Option C (Early menarche and late menopause):** Both conditions extend the "estrogen window." Early menarche (before age 12) and late menopause (after age 55) increase the total duration of hormonal stimulation on breast tissue. * **Option D (Nulliparous women):** Women who have never carried a pregnancy to term are at a higher risk compared to multiparous women because they do not experience the protective hormonal "rest" and cellular differentiation provided by pregnancy. **High-Yield Clinical Pearls for NEET-PG:** * **Gail Model:** The most commonly used tool to estimate the 5-year and lifetime risk of invasive breast cancer. * **Protective Factors:** Early pregnancy, prolonged breastfeeding, and regular physical activity. * **High-Risk Factors:** Atypical ductal hyperplasia (ADH) and Lobular carcinoma in situ (LCIS) carry a high risk for future invasive cancer. * **Li-Fraumeni Syndrome:** Associated with **p53 mutations**, leading to early-onset breast cancer and sarcomas.

Question 57: Which of the following statements is true regarding male breast cancer?

A. It is associated with Klinefelter's syndrome (XXY). (Correct Answer)
B. Infiltrating ductal carcinoma is seen in 15% of cases.
C. It is commonly seen in young males.
D. The primary treatment is medical.

Explanation: ### Explanation **Correct Option: A. It is associated with Klinefelter's syndrome (XXY).** Male breast cancer is rare, accounting for <1% of all breast cancers. The strongest risk factor is **Klinefelter’s syndrome (47, XXY)**, which increases the risk by approximately 20–50 times compared to the general male population. This is due to the altered estrogen-to-androgen ratio (hyperestrogenism) characteristic of the syndrome. **Analysis of Incorrect Options:** * **B. Infiltrating ductal carcinoma (IDC) is seen in 15% of cases:** This is incorrect. **IDC is the most common histological type**, accounting for over **80–90%** of cases. Conversely, Lobular carcinoma is extremely rare in males because the male breast lacks developed terminal lobules. * **C. It is commonly seen in young males:** This is incorrect. Male breast cancer typically presents in the **6th or 7th decade** of life (average age 60–65 years), which is generally older than the average age of presentation in females. * **D. The primary treatment is medical:** This is incorrect. The primary treatment is **surgical**, typically a **Modified Radical Mastectomy (MRM)**. Medical management (like Tamoxifen) is used as adjuvant therapy, as roughly 90% of male breast cancers are Estrogen Receptor (ER) positive. **High-Yield Clinical Pearls for NEET-PG:** * **Genetic Risk:** *BRCA2* mutations are more strongly associated with male breast cancer than *BRCA1*. * **Presentation:** Most common presentation is a painless, firm subareolar lump (eccentric lumps are more likely to be gynecomastia). * **Staging & Prognosis:** Staging is the same as in females; however, males often present at a later stage due to lack of awareness, leading to a poorer overall prognosis. * **Histology:** Papillary carcinoma is more common in men than in women.

Question 58: A 35-year-old female has ductal carcinoma in situ of the breast with diffuse microcalcifications. What is the best possible management?

A. Breast conservative surgery
B. Simple mastectomy (Correct Answer)
C. Modified radical mastectomy
D. Radiotherapy

Explanation: ### Explanation The correct management for this patient is **Simple Mastectomy**. **Why Simple Mastectomy is the Correct Choice:** Ductal Carcinoma In Situ (DCIS) is a non-invasive malignancy. While Breast Conservative Surgery (BCS) is often preferred for localized DCIS, the presence of **diffuse microcalcifications** indicates extensive or multicentric disease. In such cases, achieving negative surgical margins with BCS is nearly impossible without significant cosmetic deformity. Therefore, a Simple Mastectomy (removal of the entire breast tissue including the nipple-areola complex, without axillary lymph node dissection) is the treatment of choice to ensure complete resection. **Analysis of Incorrect Options:** * **A. Breast Conservative Surgery:** Contraindicated in DCIS with diffuse/widespread microcalcifications, multicentric disease, or when the tumor-to-breast ratio is unfavorable. * **C. Modified Radical Mastectomy (MRM):** This involves axillary lymph node dissection (ALND). Since DCIS is a non-invasive (pre-invasive) condition, the risk of axillary metastasis is negligible (<1%), making ALND unnecessary and overly morbid. * **D. Radiotherapy:** While radiotherapy is used *after* BCS to reduce local recurrence, it is not a standalone primary treatment for DCIS. **High-Yield Clinical Pearls for NEET-PG:** * **DCIS Hallmark:** Microcalcifications on mammography (typically pleomorphic or linear/branching). * **Sentinel Lymph Node Biopsy (SLNB):** Not routinely required for DCIS, but should be considered if a mastectomy is planned (as the primary site is removed, making a later SLNB impossible if invasive cancer is found on final pathology). * **Van Nuys Prognostic Index:** Used to determine the risk of local recurrence and guide the choice between BCS alone, BCS + Radiation, or Mastectomy. * **Comedo subtype:** The most aggressive histological subtype of DCIS with a higher risk of progression to invasive carcinoma.

Question 59: A female is presented with a breast lump of size 2 cm with no lymphadenopathy and no metastasis. What is her TNM staging?

A. T2 N0 M0
B. T3 N0 M0 (Correct Answer)
C. T4a N0 M0
D. T4b N0 M0

Explanation: ### Explanation The TNM staging system for breast cancer (AJCC 8th Edition) is a critical high-yield topic for NEET-PG. Staging is primarily determined by the size of the primary tumor (T), involvement of regional lymph nodes (N), and presence of distant metastasis (M). **Why T3 N0 M0 is Correct:** In the TNM classification for breast cancer: * **T (Tumor):** T1 is ≤ 2 cm; T2 is > 2 cm but ≤ 5 cm; **T3 is > 5 cm**. * **N (Nodes):** N0 indicates no regional lymph node metastasis. * **M (Metastasis):** M0 indicates no distant metastasis. **Note on the Question Logic:** While the question states the lump is **2 cm** (which typically classifies as **T1c**), the provided "Correct Answer" is **T3**. In competitive exams like NEET-PG, if the key indicates T3, it often implies a typographical error in the question stem (where 2 cm was likely meant to be > 5 cm) or follows a specific previous year's key. Based strictly on the 2 cm measurement, the staging should be T1 N0 M0. However, to align with the provided key (T3), the tumor size would need to be **> 5 cm**. **Analysis of Incorrect Options:** * **T2 N0 M0:** Incorrect because T2 represents a tumor size between 2.1 cm and 5 cm. * **T4a N0 M0:** Incorrect because T4a implies extension to the chest wall (ribs, intercostal muscles, or serratus anterior). * **T4b N0 M0:** Incorrect because T4b implies edema (including peau d'orange) or ulceration of the skin of the breast. **Clinical Pearls for NEET-PG:** 1. **T1 Categories:** T1mic (≤ 0.1 cm), T1a (0.1–0.5 cm), T1b (0.5–1 cm), T1c (1–2 cm). 2. **T4 Classification:** T4a (Chest wall), T4b (Skin involvement), T4c (Both 4a and 4b), T4d (Inflammatory carcinoma). 3. **N1 vs N2:** N1 involves movable axillary nodes; N2 involves fixed/matted axillary nodes or internal mammary nodes. 4. **Early Breast Cancer:** Includes Stage I, IIA, and IIB (T2N1 or T3N0).

Question 60: A woman presents with a recent delivery and develops a fever along with an engorged, shiny mass on her breast under the nipple. What is the most likely diagnosis?

A. Breast abscess (Correct Answer)
B. Fibroadenosis
C. Sebaceous cyst
D. Fibroadenoma

Explanation: ### Explanation **Correct Answer: A. Breast abscess** **Reasoning:** The clinical presentation of a **recent delivery** (lactation period), **fever**, and a **painful, engorged, shiny mass** is classic for a lactational breast abscess. During breastfeeding, cracks or fissures in the nipple allow skin flora (most commonly *Staphylococcus aureus*) to enter the breast tissue. If mastitis is not treated promptly, it progresses to an abscess. The "shiny" appearance of the skin indicates underlying tension and inflammation, while the subareolar location (under the nipple) is common due to the convergence of lactiferous ducts. **Why the other options are incorrect:** * **B. Fibroadenosis (AND/Fibrocystic disease):** This typically presents as cyclical mastalgia (pain related to the menstrual cycle) and "lumpy" breasts in premenopausal women. It does not present with fever or acute inflammatory signs. * **C. Sebaceous cyst:** While these can occur on the breast skin, they are usually slow-growing, painless (unless infected), and characterized by a central punctum. They are not specifically associated with recent delivery. * **D. Fibroadenoma:** Known as the "Breast Mouse," this is a benign, highly mobile, firm, and painless lump. It is a proliferative lesion, not an infectious one, and does not cause fever. **NEET-PG High-Yield Pearls:** * **Most common organism:** *Staphylococcus aureus*. * **Management:** The gold standard is **Incision and Drainage (I&D)** using a radial incision (to avoid duct damage) or ultrasound-guided needle aspiration. * **Breastfeeding Advice:** Contrary to old myths, the mother should **continue breastfeeding** or use a breast pump to prevent further stasis, unless there is frank pus discharging from the nipple. * **Antibiotic of choice:** Flucloxacillin or Erythromycin (if penicillin-allergic).

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free